NCT06771115View on ClinicalTrials.gov

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

176

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Obesity

Interventions

DRUG

VTX3232 Dose A

VTX3232 Dose A

DRUG

Placebo

Placebo

DRUG

VTX3232 Dose A in combination with semaglutide

VTX3232 Dose A in combination with semaglutide

DRUG

Placebo in combination with semaglutide

Placebo in combination with semaglutide

Trial Locations (14)

32127

840016, Port Orange

33761

840001, Largo

34761

840012, Ocoee

35235

840005, Birmingham

67114

840014, Newton

70072

840015, Marrero

840017, Marrero

75230

840006, Dallas

76710

840010, Waco

78229

840013, San Antonio

840018, San Antonio

78705

840002, Austin

90815

840011, Long Beach

92630

840003, Lake Forest

All Listed Sponsors

lead

Zomagen Biosciences Ltd.

INDUSTRY

NCT06771115 - Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity | Biotech Hunter | Biotech Hunter